dalteparin has been researched along with Malignant Melanoma in 8 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental metastasis of MV3 cells in mice confirmed the relevance of VLA-4 for metastatic dissemination." | 1.38 | The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. ( Bendas, G; Casu, B; Naggi, A; Schlesinger, M; Schmitz, P; Torri, G; Zeisig, R, 2012) |
| " Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice." | 1.33 | Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. ( Choi, SH; Stevenson, JL; Varki, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ataabadi, FV | 1 |
| Oveissi, F | 1 |
| Etebari, M | 1 |
| Taheri, A | 1 |
| Kerk, N | 1 |
| Strozyk, EA | 1 |
| Pöppelmann, B | 1 |
| Schneider, SW | 2 |
| Schlesinger, M | 2 |
| Schmitz, P | 3 |
| Zeisig, R | 1 |
| Naggi, A | 2 |
| Torri, G | 2 |
| Casu, B | 1 |
| Bendas, G | 3 |
| Wojtukiewicz, MZ | 1 |
| Kozlowski, L | 1 |
| Ostrowska, K | 1 |
| Dmitruk, A | 1 |
| Zacharski, LR | 1 |
| Gerber, U | 1 |
| Schütze, N | 1 |
| Jüngel, E | 1 |
| Blaheta, R | 1 |
| Bauer, AT | 1 |
| Suckau, J | 1 |
| Frank, K | 1 |
| Desch, A | 1 |
| Goertz, L | 1 |
| Wagner, AH | 1 |
| Hecker, M | 1 |
| Goerge, T | 1 |
| Umansky, L | 1 |
| Beckhove, P | 1 |
| Utikal, J | 1 |
| Gorzelanny, C | 1 |
| Diaz-Valdes, N | 1 |
| Umansky, V | 1 |
| Simonis, D | 1 |
| Fritzsche, J | 1 |
| Stevenson, JL | 1 |
| Choi, SH | 1 |
| Varki, A | 1 |
1 trial available for dalteparin and Malignant Melanoma
| Article | Year |
|---|---|
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; C | 2003 |
7 other studies available for dalteparin and Malignant Melanoma
| Article | Year |
|---|---|
Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma.
Topics: Chitosan; Dacarbazine; Drug Delivery Systems; Enoxaparin; Humans; Melanoma; Nanoparticles | 2023 |
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
Topics: Anticoagulants; Cell Line, Tumor; Endothelial Cells; Enoxaparin; Flow Cytometry; Heparin; Heparin, L | 2010 |
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Topics: Acetylation; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Cell Adhesion; Cell Line, T | 2012 |
Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Topics: Anticoagulants; Carcinogenesis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cysteine-Rich Protei | 2013 |
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.
Topics: ADAM Proteins; ADAMTS13 Protein; Animals; Blood Coagulation; Blood Platelets; Disease Models, Animal | 2015 |
Binding between heparin and the integrin VLA-4.
Topics: Acoustics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biosensing Techniques; Cell Ad | 2009 |
Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Topics: Animals; Anticoagulants; Cell Line, Tumor; Disaccharides; Factor Xa; Fibrinolytic Agents; Fondaparin | 2005 |